1. At a Glance – The Lab Report Nobody Ordered
₹645 Cr market cap. ₹176 stock price. Down 21.7% in 3 months. Down 22.5% in 6 months. Five-year return? A painful –17% CAGR.
Welcome to the fascinating world of Chemcon Speciality Chemicals Ltd, where the company is the largest manufacturer of HMDS and CMIC globally, but the stock behaves like it forgot its own chemical formula.
Latest Q3 FY26 numbers?
- Sales: ₹57.33 Cr
- PAT: ₹5.09 Cr
- Quarterly profit down 42% YoY
- ROCE: 7.01%
- ROE: 5%
- P/E: 30.4
- Debt: ₹0.26 Cr (basically zero)
This is a company that dominates niche chemicals but struggles to dominate its own margin chart. Inventory days have ballooned. Cash conversion cycle looks like it ran a marathon without training. And yet — zero debt.
So here’s the big question:
Is this a temporary slowdown in specialty chemicals, or are we staring at a premium P/E attached to a modest growth story?
Let’s put on our gloves and enter the lab.
2. Introduction – The Chemical That Time Forgot?
Chemcon Speciality Chemicals was incorporated in 1988. That’s older than most startup founders today. And unlike new-age chemical stories, this one isn’t chasing fashion trends.
They manufacture:
- Pharmaceutical intermediates
- Agro intermediates
- Oilfield chemicals
- Silanes
They are:
- Only manufacturer of HMDS in India
- 3rd largest HMDS manufacturer globally
- Largest CMIC manufacturer worldwide
- Only Zinc Bromide manufacturer in India
- Largest Calcium Bromide manufacturer in India
That sounds like a monopoly buffet.
So why is the stock sleepy?
Because being a global leader in niche chemicals doesn’t automatically guarantee high growth every quarter. Specialty chemicals are cyclical. Pharma intermediates depend on customer pipelines. Oilfield chemicals depend on drilling activity.
And here’s something interesting:
Top 5 customers contribute 30% revenue. Top 10 contribute 45%.
That’s concentration. That’s dependency. That’s bargaining power sitting on the client’s side of the table.
Exports contribute 35%. Domestic is 65%.
They’re trying to reduce customer concentration. But the question is — can they accelerate volume growth while maintaining pricing?
Let’s see what the numbers say.
3. Business Model – WTF Do They Even Do?
Okay, imagine this.
Big pharma companies need very specific chemical ingredients to manufacture antiviral drugs. These are not chemicals you buy from a wholesale market.
Chemcon manufactures:
Organic Chemicals (78% of H1FY26 revenue)
- HMDS
- CMIC
- Bromobenzene
- 2-Bromo (new product added in FY25 with 600 MTPA capacity)
End users? Pharma and agrochemical companies.
Clients include:
- Hetero
- Laurus Labs
- Aurobindo
- Macleods
So basically, if pharma is cooking something complex,
